Defer to Technicals<br />By Rev Shark<br />RealMoney.com Contributor<br />12/18/2007 8:40 AM EST <br /><br /><br />However beautiful the strategy, you should occasionally look at the results. <br />-- Winston Churchill<br /><br />In this very difficult market environment, it is quite easy to let "hope" become your primary investing strategy. As the market has broken down, the easiest course of action is to simply hold on to stocks that have pulled back and hope that the market will eventually see the errors of its ways and push them back to the price they rightfully deserve. We know that the market is not properly valuing our stocks, and if we can just hold on, things will eventually return to normal. <br /><br />The biggest problem with this investing approach is that it assumes that the market is a rational beast. The market can go for extremely long periods without recognizing the values that seem so painfully obvious to us. <br /><br />Many investors -- including me -- have learned the lesson over and over again that "cheap" stocks often become even cheaper. Great bargains become better bargains and end up staying that way for a very long time. <br /><br />The problem is that when the market is acting poorly, many investors simply don't care about "values." They see losses mounting and they want out regardless of valuation or future prospects. Investors react to price action far more so than they react to analysis. <br /><br />The way to deal with this is to defer to technical action and use "valuation" as a secondary consideration. When a stock breaks down, don't talk yourself into holding simply because it's a value. Cut some of your position and look at adding it back only after the chart has found some support and buying interest returns. <br /><br />We are in a very tough market right now, and many stocks, especially the more illiquid small-caps, are pulling back sharply. Some are great values, but you need a sound strategy for buying or holding them. You can't just rely on the hope that the market will realize that they are cheap and drive them back up. Stocks recover because the market is in an uptrend, not because there is a sudden realization that they are cheap. <br /><br />It is far more important that the market be cooperative than it is that we buy "cheap" stocks. Keep that in mind as you craft your strategy in these difficult times. <br /><br />We have a good bounce to start the day after yesterday's very dismal action. We were looking awfully negative yesterday, but overseas markets have come back and earnings from Best Buy (BBY) and Goldman Sachs (GS) are helping matters this morning. We are due for a bounce, but the big question is how long will it last. <br />-----------------------------<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance: ZANE +14.7%, BBY +2.2%, ADBE +2.1% (also announces additional share repurchase authorization of 30 million shares), TFSL +1.8%, GS +1.6%, DLLR +1.0%... M&A news: EICU +29.8% (agrees to be acquired by PHG for $12.00/share), WWIN +20.9% (announces agreement to go private for $38.00/share)... Other news: IRBT +16.3% (wins $286 mln U.S. Army contract), TMA + 9.3% (reinstates its common stock dividend), MICC +6.9% (still checking), GMO +6.3% (announces letter of intent for formation of joint venture with POSCO for Mount Hope Project), JASO +5.0% (inks new wafer supply agreement with ReneSola), RRC +5.0% (will replace TRB in the S&P 500 after the close on 12/20), DRYS +4.6% (Jefferies out with positive piece on DRYS; reiterate Buy, $160 tgt), FSLR +3.5% (Cramer makes positive comments on MadMoney), PHTN +3.4% (delays 10-K filing), RTP +3.4% (still checking), KWK +3.2% (announces 2008 capital budget which includes approx $650 mln for drilling), FRX +2.9% (FDA approves nebivolol for high blood pressure - DJ, also upgraded to Buy at Soleil), MT +2.8% (announces start of 44 mln share buyback program), STP +2.6% (tgt raised to $100 at Lehman), EME +2.6% (announces that its subsidiary received a three-yr contract from the US Air Force), BHP +2.5% (still checking), S +2.1% (names Dan Hesse as President and CEO). Analyst upgrades: MFLX +8.1% (initiated with Buy at BofA), SYMC +2.9% (upgraded to Peer Perform at Bear Sterns), GLF +2.6% (assumed and upgraded to Buy at BofA), NOV +2.4% (upgraded to Buy at Calyon), OTEX +2.3% (upgraded to Outperform at Raymond James).<br /><br />Allapoole avanevad:<br /><br />In reaction to strong earnings/guidance: TUES -20.4%, SNV -9.1%, WPCS -5.8%, MFRI -4.9%... Other news: TRMP -8.0% (Moody's reviewing debt rating for possible cut), MLNM -4.0% (held investor meeting yesterday), SCON -2.5% (files $80 mln mixed securities shelf offering in S3), AGO -1.3% (agrees to sell 11,764,705 of its common shares in an offering at $25.50)... Analyst downgrades: ZGEN -4.1% (downgraded to Neutral at BofA, also begins Phase II Trial of IL-21 n Melanoma), LNCR -1.5% (downgraded to Neutral at Oppenheimer), WIBC -1.3% (initiated with Sell at Merrill).